Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 05:54 ET | Source: Research and Markets

Breast Cancer Antibody Drug Conjugates Market Research 2025-2030: $7 Billion Market Led by Daiichi Sankyo and AstraZeneca, with Rising Competition from Roche, Pfizer/Seagen, ADC Therapeutics

Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added...
October 21, 2025 05:34 ET | Source: Research and Markets

Tumor Infiltrating Lymphocytes Therapy Market Research Report 2025-2030: Market Driven by Active R&D from Iovance Biotherapeutics, Juncell Therapeutics, Biosyngen, and Instil Bio

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity, Proprietary Technologies Platforms & Clinical Trials Insight 2030" report has...
October 20, 2025 09:54 ET | Source: Research and Markets

DNA Cancer Vaccine Clinical Trials & Market Opportunity Outlook 2026 | First Commercial Approval of DNA Cancer Vaccine Anticipated by 2030

Dublin, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The "DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026" report has been added to ...
October 10, 2025 04:54 ET | Source: Research and Markets

Menin Inhibitors Drug Market Report 2025: Price, Sales & Clinical Trials Insights 2024-2028 - Kura Oncology & Kyowa Kirin Progress with New Drug Applications

Dublin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The "Menin Inhibitors Drug Market, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.Report...
October 01, 2025 05:13 ET | Source: Research and Markets

CD47 Inhibitors Drug Market & Clinical Trials Insight 2026, Featuring Adagene, Akeso, ALX Oncology, EpicentRx, ImmuneOncia, ImmuneOnco Biopharma, Phanes Therapeutics, Virtuoso Therapeutics, and More

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "CD47 Inhibitors Drug Market Opportunity, Clinical Application by Indications & Clinical Trials Insight 2026" report has been added to ...
October 01, 2025 04:11 ET | Source: Research and Markets

Lymphoma Antibody Drug Conjugates Market Clinical Trials Insight 2030, by Company, Country, Indication and Phase

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added to ...
September 22, 2025 13:00 ET | Source: Applied Pharmaceutical Innovation (API)

API Launches the Life Sciences Placement Program in Partnership with Mitacs at the Life Sciences Week Kick-Offs

In partnership with Mitacs, Applied Pharmaceutical Innovation (API) launched the Life Sciences Placement Program, set to provide 1,000 new internships.
July 21, 2025 07:23 ET | Source: Research and Markets

CD5 Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025 | CD5 Therapies Reach Phase-II Trials with Less Than 10 in Pipeline

Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "CD5 Targeting Therapies Market Trends, Clinical Trials, Technology Platforms & Future Outlook 2025" report has been added to ...
July 09, 2025 09:17 ET | Source: Research and Markets

Peptide Drug Conjugate Markets, Drug Sales, Price, Dosage & Clinical Trials Insights, 2018-2024 & 2025-2030 with Focus on Clinical & Commercial Insight of Lutathera and Pepaxto/Pepaxti

Dublin, July 09, 2025 (GLOBE NEWSWIRE) -- The "Peptide Drug Conjugate Market, Drug Sales, Price, Dosage & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's...
June 25, 2025 07:55 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...